Correlation ofKi-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - areview of137 cases.

Abstract

Theuse ofchemotherapy in breast cancer management has significantly contributed to thedecrease in its mortality. Currently, theprognosis is determined by molecular biomarkers, such as oestrogen receptors, and human epidermal growth factor receptor 2. However, theincreasing use ofadvanced molecular technologies, including oncotype DX recurrence score (ODX-RS), has provided theability to estimate therisk ofrecurrence. Research has demonstrated that theODX-RS helps to predict recurrence risk and thepotential benefit ofchemotherapy in breast cancer. As aresult, it can assist clinicians in making decisions regarding using thechemotherapy. Thegoal ofwork is to explore thecorrelation between theODX-RS and Ki-67 proliferative index (Ki-67-PI). This study included 137 patients with oestrogen positive, human epidermal growth factor receptor 2-negative early breast cancer, and had non- or early axillary disease. Patients with low Ki-67-PI were as follows: low ODX-RS in 17%, intermediate ODX-RS in 80%, and high ODX-RS in 2%. In thehigh Ki-67-PI group: low ODX-RS in 12%, intermediate ODX-RS in 48%, and high ODX-RS in 40%. In conclusion, theresults show no significant correlation between theODX-RS and Ki-67-PI (r = 0.511, p-value < 0.9).